Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer

References

• Advani SJ, Mezhir JJ, Roizman B, Weichselbaum RR. 2006. ReVOLT: Radiation-enhanced viral oncolytic therapy. International Journal of Radiation Oncology Biology Physics 66:637–646.
   PubMed Web of Science ®Google Scholar
• Boyer J, Rohleder K, Ketner G. 1999. Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase. Virology 263:307–312.
   PubMed Web of Science ®Google Scholar
• Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. 2004. Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10:33–39.
   PubMed Web of Science ®Google Scholar
• Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N, Lee J, Pennathur-Das R, Radzyminski J, Wypych J, Brignetti D, Scott S, Stephens J, Karpf DB, Henderson DR, Yu DC. 2001. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Research 61:5453–5460.
   PubMed Web of Science ®Google Scholar
• Collis SJ, Swartz MJ, Nelson WG, DeWeese TL. 2003. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Research 63:1550–1554.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. 2004. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. Journal of Clinical Oncology 22:2141–2149.
   PubMed Web of Science ®Google Scholar
• DeWeese TL, Shipman JM, Dillehay LE, Nelson WG. 1998. Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure. Journal of Urology 159:591–598.
   PubMed Web of Science ®Google Scholar
• DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo AM, Piantadosi S, Yu DC, Chen Y, Henderson DR, Carducci MA, Nelson WG, Simons JW. 2001. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Research 61:7464–7472.
   PubMed Web of Science ®Google Scholar
• Egami T, Ohuchida K, Mizumoto K, Onimaru M, Toma H, Nishio S, Nagai E, Matsumoto K, Nakamura T, Tanaka M. 2008. Radiation enhances adenoviral gene therapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake. Clinical Cancer Research 14:1859–1867.
   PubMed Web of Science ®Google Scholar
• Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D, Hoeben RC. 1998. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Human Gene Therapy 9:1909–1917.
   PubMed Web of Science ®Google Scholar
• Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J, Zhang Y, Barton KN, Brown SL, Lu M, Savera A, Kim JH. 2007. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Molecular Therapy 15:1016–1023.
   PubMed Web of Science ®Google Scholar
• Hart LS, Ornelles D, Koumenis C. 2007. The adenoviral E4orf6 protein induces atypical apoptosis in response to DNA damage. Journal of Biological Chemistry 282:6061–6067.
   PubMed Web of Science ®Google Scholar
• Hart LS, Yannone SM, Naczki C, Orlando JS, Waters SB, Akman SA, Chen DJ, Ornelles D, Koumenis C. 2005. The adenovirus E4orf6 protein inhibits DNA double strand break repair and radiosensitizes human tumor cells in an E1B-55K-independent manner. Journal of Biological Chemistry 280:1474–1481.
   PubMed Web of Science ®Google Scholar
• He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. 1998. A simplified system for generating recombinant adenoviruses. Proceedings of the National Academy of Sciences of the USA 95:2509–2514.
   PubMed Web of Science ®Google Scholar
• Hoti N, Li Y, Chen CL, Chowdhury WH, Johns DC, Xia Q, Kabul A, Hsieh JT, Berg M, Ketner G, Lupold SE, Rodriguez R. 2007. Androgen receptor attenuation of Ad5 replication: Implications for the development of conditionally replication competent adenoviruses. Molecular Therapy 15:1495–1503.
   PubMed Web of Science ®Google Scholar
• Idema S, Geldof AA, Dirven CM, van der Jagt M, Gerritsen WR, Vandertop WP, Lamfers ML. 2007. Evaluation of adenoviral oncolytic effect on glioma spheroids by 18F-DG positron-emission tomography. Oncology Research 16:471–477.
   PubMed Web of Science ®Google Scholar
• Lebedeva IV, Emdad L, Su ZZ, Gupta P, Sauane M, Sarkar D, Staudt MR, Liu SJ, Taher MM, Xiao R, Barral P, Lee SG, Wang D, Vozhilla N, Park ES, Chatman L, Boukerche H, Ramesh R, Inoue S, Chada S, Li R, De Pass AL, Mahasreshti PJ, Dmitriev IP, Curiel DT, Yacoub A, Grant S, Dent P, Senzer N, Nemunaitis JJ, Fisher PB. 2007. mda-7/IL-24, novel anticancer cytokine: Focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). International Journal of Oncology 31:985–1007.
   PubMed Web of Science ®Google Scholar
• Maggiorella L, Deutsch E, Frascogna V, Chavaudra N, Jeanson L, Milliat F, Eschwege F, Bourhis J. 2003. Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo. Cancer Research 63:2513–2517.
   PubMed Web of Science ®Google Scholar
• Nagano S, Perentes JY, Jain RK, Boucher Y. 2008. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Research 68:3795–3802.
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Zietman AL. 2007. High-dose external beam radiation for localized prostate cancer: Current status and future challenges. Cancer Journal 13:295–301.
   PubMed Web of Science ®Google Scholar
• O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D, McCormick F. 2004. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6:611–623.
   PubMed Web of Science ®Google Scholar
• Qian J, Yang J, Dragovic AF, Abu-Isa E, Lawrence TS, Zhang M. 2005. Ionizing radiation-induced adenovirus infection is mediated by Dynamin 2. Cancer Research 65:5493–5497.
   PubMed Web of Science ®Google Scholar
• Querido E, Blanchette P, Yan Q, Kamura T, Morrison M, Boivin D, Kaelin WG, Conaway RC, Conaway JW, Branton PE. 2001a. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes & Development 15:3104–3117.
   PubMed Web of Science ®Google Scholar
• Querido E, Morrison MR, Chu-Pham-Dang H, Thirlwell SW, Boivin D, Branton PE. 2001b. Identification of three functions of the adenovirus e4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex. Journal of Virology 75:699–709.
   PubMed Web of Science ®Google Scholar
• Rajecki M, Kanerva A, Stenman UH, Tenhunen M, Kangasniemi L, Sarkioja M, Ala-Opas MY, Alfthan H, Sankila A, Rintala E, Desmond RA, Hakkarainen T, Hemminki A. 2007. Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. Molecular Cancer Therapeutics 6:742–751.
   PubMed Web of Science ®Google Scholar
• Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. 1997. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Research 57:2559–2563.
   PubMed Web of Science ®Google Scholar
• Shewach DS, Lawrence TS. 2007. Antimetabolite radiosensitizers. Journal of Clinical Oncology 25:4043–4050.
   PubMed Web of Science ®Google Scholar
• Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G. 2006. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Molecular Therapy 14:107–117.
   PubMed Web of Science ®Google Scholar
• Teh BS, Amosson CM, Mai WY, McGary J, Grant WH 3rd, Butler EB. 2004. Intensity modulated radiation therapy (IMRT) in the management of prostate cancer. Cancer Investigation 22:913–924.
   PubMed Web of Science ®Google Scholar
• van Beusechem VW, Grill J, Mastenbroek DC, Wickham TJ, Roelvink PW, Haisma HJ, Lamfers ML, Dirven CM, Pinedo HM, Gerritsen WR. 2002. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. Journal of Virology 76:2753–2762.
   PubMed Web of Science ®Google Scholar
• Wu L, Matherly J, Smallwood A, Adams JY, Billick E, Belldegrun A, Carey M. 2001. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Therapy 8:1416–1426.
   PubMed Web of Science ®Google Scholar
• Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. 2002. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Research 62:1008–1013.
   PubMed Web of Science ®Google Scholar